As a result of TROPiCs-02 data, SG is approved for patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer who received endocrine-based therapy and at least two additional chemotherapies in the metastatic setting. Here, ERBB2 is linked to breast cancer.